Eagle Pharmaceuticals (EGRX) stock price, revenue, and financials

Eagle Pharmaceuticals market cap is $615 m, and annual revenue was $195.89 m in FY 2019

$615 M

EGRX Mkt cap, 27-Nov-2020

$17.3 M

Eagle Pharmaceuticals Revenue Q3, 2020
Eagle Pharmaceuticals Cash, 30-Sept-202089.7 M
Eagle Pharmaceuticals EV563.2 M

Eagle Pharmaceuticals Revenue

Eagle Pharmaceuticals revenue was $195.89 m in FY, 2019

Embed Graph

Eagle Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.1m66.2m189.5m236.7m213.3m195.9m

Revenue growth, %

247%186%

Cost of goods sold

11.7m15.6m34.3m33.7m42.4m47.9m

Gross profit

7.4m50.6m155.2m203.0m170.9m148.0m

Gross profit Margin, %

39%76%82%86%80%76%

R&D expense

16.8m27.9m30.3m32.6m44.4m36.8m

General and administrative expense

9.3m20.2m52.3m71.4m60.5m76.4m

Operating expense total

26.1m48.0m101.8m129.0m134.3m126.2m

EBIT

(18.8m)2.6m53.4m74.0m36.6m21.8m

EBIT margin, %

(98%)4%28%31%17%11%

Interest expense

76.0k1.0m2.6m183.0k

Interest income

31.0k25.0k84.0k91.0k158.0k2.2m

Pre tax profit

(19.3m)2.6m53.4m72.9m34.0m22.0m

Income tax expense

(1.3m)3.0k(28.0m)21.0m2.1m7.7m

Net Income

(18.0m)2.6m81.5m51.9m31.9m14.3m

Quarterly

USDQ2, 2014Q3, 2014Q4, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.0m5.8m5.6m36.3m6.0m5.7m29.6m40.9m37.8m76.8m50.1m63.0m46.6m59.3m51.3m49.8m56.7m41.1m46.0m14.4m17.3m

Cost of goods sold

3.4m1.6m4.5m5.9m3.3m3.8m14.6m11.5m10.4m10.8m8.9m4.8m7.2m14.1m8.6m9.6m18.2m12.1m4.8m

Gross profit

1.6m4.2m1.1m30.4m2.7m2.0m15.0m29.4m27.4m66.0m41.2m58.2m39.4m45.2m42.7m40.2m38.5m29.0m41.3m

Gross profit Margin, %

33%73%20%84%44%35%51%72%72%86%82%92%85%76%83%81%68%71%90%

Sales and marketing expense

626.0k

R&D expense

3.8m4.5m4.0m6.3m5.9m6.9m6.7m3.7m3.2m7.5m6.7m9.0m17.3m15.3m6.0m6.4m9.0m10.2m9.4m

General and administrative expense

1.5m2.7m3.7m4.0m5.1m5.5m11.0m12.1m11.9m18.6m23.7m16.7m15.2m16.0m13.9m18.1m17.2m18.5m24.8m

Operating expense total

5.2m7.2m7.7m10.3m11.0m12.4m15.9m15.8m15.1m33.3m35.3m33.3m37.1m45.0m24.3m28.1m29.3m31.5m37.2m

EBIT

(3.6m)(3.0m)(6.6m)20.1m(8.3m)(10.4m)(897.0k)13.7m12.3m32.7m5.9m25.0m2.3m183.0k18.4m12.2m9.2m(2.5m)4.0m

EBIT margin, %

(72%)(51%)(117%)55%(139%)(181%)(3%)33%33%43%12%40%5%0%36%24%16%(6%)9%

Interest expense

1.0k6.0k5.0k3.0k20.0k27.0k3.0k27.0k26.0k492.0k648.0k700.0k734.0k686.0k28.0k58.0k

Interest income

7.6k17.8k1.0k7.0k8.0k8.0k21.0k30.0k26.0k3.0k14.0k35.0k27.0k1.0k9.0k494.0k637.0k570.0k346.0k

Pre tax profit

(4.0m)(2.9m)(6.6m)20.1m(8.3m)(10.4m)(877.0k)13.7m12.3m32.7m5.9m24.5m1.7m(517.0k)17.7m12.0m9.2m(2.5m)(3.0m)

Income tax expense

(1.3m)(1.1m)399.0k(153.0k)(218.0k)19.0k584.0k379.0k9.7m1.4m9.0m(959.0k)(3.2m)3.6m3.0m2.5m(152.0k)(137.0k)

Net Income

(2.7m)(2.9m)(5.5m)19.7m(8.2m)(10.2m)(896.0k)13.1m12.0m22.9m4.5m15.4m2.6m2.7m14.0m9.0m6.7m(2.4m)(2.9m)

Eagle Pharmaceuticals Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

22.7m79.1m52.8m114.7m78.8m109.8m

Accounts Receivable

7.3m26.3m42.2m53.8m66.5m48.0m

Prepaid Expenses

1.7m15.1m10.3m15.1m

Inventories

1.3m15.0m11.4m5.1m8.3m6.6m

Current Assets

53.0m122.3m109.1m188.7m163.8m179.4m

PP&E

344.0k2.2m3.3m6.8m2.4m2.2m

Goodwill

39.7m39.7m39.7m39.7m

Total Assets

53.4m124.6m214.3m270.1m238.6m254.6m

Accounts Payable

4.1m3.9m14.7m12.0m9.9m5.5m

Short-term debt

4.9m6.3m5.0m

Current Liabilities

20.3m34.3m41.0m47.3m39.7m38.8m

Long-term debt

42.9m38.2m36.6m

Total Debt

4.9m6.3m41.6m

Total Liabilities

75.4m

Common Stock

14.0k16.0k17.0k17.0k

Preferred Stock

Additional Paid-in Capital

137.3m197.4m213.9m233.6m256.5m278.5m

Retained Earnings

(104.2m)(107.1m)(25.7m)26.3m58.2m72.5m

Total Equity

33.1m90.3m151.2m179.1m160.8m179.2m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.6 x1.4 x1.4 x1.5 x1.5 x1.4 x

Quarterly

USDQ2, 2014Q3, 2014Q4, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

54.9m49.8m34.9m99.9m13.7m72.0m78.3m75.6m59.3m27.7m55.4m97.5m95.7m100.2m91.2m102.1m108.1m117.2m202.0m108.2m89.7m

Accounts Receivable

7.8m6.7m12.0m10.5m13.0m12.2m26.5m52.0m47.1m84.7m53.2m71.6m53.4m69.4m78.5m63.9m60.3m44.8m54.5m46.8m52.2m

Prepaid Expenses

832.7k922.9k1.6m1.3m1.6m4.8m2.0m1.5m5.6m8.1m11.7m8.1m13.6m25.5m20.8m5.9m5.6m10.5m10.6m5.6m15.3m

Inventories

329.0k1.2m2.0m2.3m7.3m7.8m6.4m7.1m3.0m3.6m4.9m6.1m6.4m7.3m10.3m11.6m7.2m8.4m7.9m6.6m

Current Assets

63.5m57.8m49.7m129.8m120.6m120.3m114.6m135.5m119.0m123.6m123.9m182.2m168.8m201.6m197.8m182.2m185.7m179.8m275.6m168.4m163.8m

PP&E

377.5k359.5k342.0k100.0k374.0k1.8m2.9m2.8m2.8m3.8m3.8m4.4m6.5m2.8m2.6m2.3m2.3m2.3m2.4m2.1m2.1m

Goodwill

39.7m39.7m39.7m39.7m39.7m39.7m39.7m39.7m39.7m39.7m39.7m39.7m

Total Assets

64.0m58.2m50.1m129.9m121.0m122.2m128.7m149.4m146.7m224.8m220.2m266.9m249.3m273.9m268.8m259.5m261.6m257.0m361.9m256.7m248.2m

Accounts Payable

2.5m2.5m3.5m5.4m4.8m14.1m10.3m11.4m13.1m19.0m12.1m8.9m9.4m18.3m7.5m16.8m17.3m11.2m9.8m13.7m13.1m

Short-term debt

104.0k260.0k461.0k5.0m6.3m6.3m5.0m5.0m5.0m4.0m116.0m7.0m8.0m

Current Liabilities

19.3m16.2m22.2m27.0m24.6m34.6m30.9m35.8m35.4m35.4m32.0m34.4m28.8m47.7m35.4m44.2m51.7m42.4m145.9m40.5m45.5m

Long-term debt

43.9m41.6m40.5m39.3m37.0m35.8m35.7m30.8m28.9m29.9m

Total Debt

104.0k260.0k461.0k5.0m6.3m6.3m5.0m5.0m40.8m39.7m146.8m35.9m37.9m

Total Liabilities

180.1m72.7m75.4m

Common Stock

14.0k14.0k14.0k15.0k15.0k15.0k15.0k15.0k15.0k16.0k16.0k16.0k16.0k16.0k16.0k17.0k17.0k17.0k17.0k17.0k17.0k

Preferred Stock

Additional Paid-in Capital

136.8m137.0m137.6m192.9m194.6m195.9m200.3m202.7m206.5m220.2m225.9m229.7m237.1m245.5m251.9m262.1m267.5m273.2m285.0m291.4m296.2m

Retained Earnings

(92.1m)(95.1m)(109.7m)(90.0m)(98.2m)(108.3m)(108.0m)(94.9m)(83.0m)(2.7m)1.8m17.2m28.9m31.6m45.6m67.2m73.9m71.5m69.6m69.4m76.4m

Total Equity

44.7m41.9m27.9m102.9m96.4m87.6m92.3m107.8m105.5m166.8m165.4m171.1m178.2m185.7m194.1m175.4m172.5m175.8m181.8m184.0m172.8m

Debt to Equity Ratio

0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x

Financial Leverage

1.4 x1.4 x1.8 x1.3 x1.3 x1.4 x1.4 x1.4 x1.4 x1.3 x1.3 x1.6 x1.4 x1.5 x1.4 x1.5 x1.5 x1.5 x2 x1.4 x1.4 x

Eagle Pharmaceuticals Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.0m)2.6m81.5m51.9m31.9m14.3m

Depreciation and Amortization

13.0k3.7m3.7m4.7m

Accounts Receivable

(2.2m)(14.3m)(15.9m)(11.6m)(12.7m)18.5m

Inventories

(1.3m)(13.8m)12.3m(2.4m)(5.6m)1.7m

Accounts Payable

2.9m356.0k10.7m(8.5m)(2.1m)(4.5m)

Cash From Operating Activities

(13.8m)(9.7m)53.2m58.9m52.4m56.0m

Purchases of PP&E

(46.0k)(1.9m)(1.6m)(4.4m)(133.0k)(777.0k)

Cash From Investing Activities

(20.0m)(1.9m)(45.8m)(5.2m)(133.0k)(777.0k)

Long-term Borrowings

(1.2m)(3.7m)(6.0m)

Cash From Financing Activities

46.2m55.8m(33.7m)8.1m(88.1m)(24.2m)

Net Change in Cash

61.8m(35.9m)31.0m

Interest Paid

1.0k651.0k2.1m2.5m

Income Taxes Paid

10.5m2.3m6.7m

Quarterly

USDQ2, 2014Q3, 2014Q4, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(5.9m)(8.9m)(5.5m)19.7m11.5m1.4m(896.0k)12.2m24.2m22.9m27.4m42.9m2.6m5.3m19.3m9.0m15.7m13.3m(2.9m)(3.1m)3.9m

Depreciation and Amortization

59.4k81.8k13.0k12.0k22.0k31.0k244.0k556.0k461.0k908.0k1.9m2.8m1.0m2.0m2.8m1.1m2.3m3.4m1.1m2.3m2.7m

Accounts Receivable

(2.7m)(1.6m)(4.7m)1.4m(1.0m)(262.0k)(259.0k)(25.8m)(20.8m)(42.5m)(11.0m)(29.4m)395.0k(15.6m)(24.6m)2.6m6.1m21.7m(6.5m)1.2m(4.2m)

Inventories

(329.0k)52.0k(776.0k)(1.1m)(6.1m)7.3m8.7m7.9m(276.0k)(848.0k)(2.1m)(1.0m)(3.4m)(4.5m)(2.0m)(3.3m)1.1m(1.9m)(1.3m)(20.0k)

Accounts Payable

1.3m1.3m(558.0k)1.9m1.3m10.6m6.4m7.6m7.7m4.3m(2.6m)(5.8m)(2.6m)6.3m(4.4m)6.9m7.4m1.3m4.3m8.2m7.6m

Cash From Operating Activities

(2.0m)(6.7m)(7.9m)25.8m13.7m7.1m3.1m484.0k13.7m(12.4m)25.1m33.0m4.9m10.6m14.3m26.2m48.6m59.2m3.2m24.1m29.7m

Purchases of PP&E

(34.6k)(38.8k)(11.0k)(43.0k)(327.0k)(1.4m)(804.0k)(904.0k)(1.1m)(676.0k)(884.0k)(1.7m)(19.0k)(19.0k)(52.0k)(177.0k)(343.0k)(647.0k)(472.0k)(376.0k)(577.0k)

Cash From Investing Activities

(34.6k)(38.8k)20.0m(16.0m)(90.3m)(25.4m)(3.9m)(4.0m)(18.2m)(676.0k)(884.0k)(2.5m)(19.0k)(19.0k)(52.0k)(177.0k)(343.0k)(647.0k)(18.0m)(17.9m)(18.1m)

Short-term Borrowings

(110.0m)(110.0m)

Long-term Borrowings

(1.2m)(3.7m)(2.5m)(3.7m)(5.0m)(1.0m)(2.0m)(3.0m)

Cash From Financing Activities

46.5m46.1m34.0k55.3m55.4m55.4m(15.2m)(12.0m)(21.7m)14.2m(23.9m)(25.0m)(37.7m)(2.7m)(18.9m)(20.1m)107.1m(7.8m)(31.8m)

Net Change in Cash

44.4m39.3m12.1m65.1m(21.2m)37.1m(796.0k)(3.5m)(19.8m)(25.1m)2.6m44.7m(19.0m)(14.4m)(23.4m)23.3m29.3m38.4m92.2m(1.6m)(20.1m)

Interest Paid

1.4k1.0k1.0k1.0k1.0k368.0k529.0k1.5m625.0k1.2m1.8m576.0k1.5m1.9m

Income Taxes Paid

2.8m5.6m8.8m96.0k1.8m1.9m(6.5m)2.9m6.6m24.0k502.0k3.0m

Eagle Pharmaceuticals Ratios

USDQ2, 2014

Financial Leverage

1.4 x